A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

This randomised, double-blind, placebo-controlled Phase III trial (n=140) will evaluate the efficacy and safety of a single oral dose of MM120 (100 µg LSD D-tartrate) for the treatment of major depressive disorder (MDD).

Conducted by MindMed (Mind Medicine, Inc.), this study will enrol adults aged 18 to 74 who are currently experiencing a moderate to severe depressive episode. Participants must meet diagnostic criteria for MDD and reach a minimum threshold on standardised depression severity scales.

The study includes a 12-week double-blind treatment phase comparing MM120 with placebo, followed by a 40-week open-label extension in which participants may receive additional MM120 doses if needed, based on symptom severity and pre-specified safety criteria. Secondary outcome measures will assess a wide range of clinical and quality-of-life domains, including depression response and remission rates, anxiety, global functioning, sexual health, work productivity, and overall wellbeing, during both the double-blind and open-label periods. This trial aims to determine whether a single dose of MM120 can offer sustained relief from depressive symptoms and improve broader aspects of daily functioning in people with MDD.

Topic Depression Safety
Compound LSD Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

MindMed
MindMed is one of the largest companies in the psychedelics space and is developing various psychedelics for mental health disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.